Cargando…
Whole-Brain Radiotherapy Combined With Anlotinib for Multiple Brain Metastases From Non-small Cell Lung Cancer Without Targetable Driver Mutation: A Single-Arm, Phase II Study
BACKGROUND: Existing evidence demonstrates that radiotherapy and antiangiogenic drugs have synergistic antitumour effects and may be a promising treatment option for patients with solid tumour. Thus, we performed a phase II trial to evaluate the efficacy and safety of whole-brain radiotherapy (WBRT)...
Autores principales: | Liu, Jianjiang, Xu, Jun, Ye, Wanli, Zhong, Wangyan, Zhang, Xiaoyu, Mao, Jiwei, Wu, Dongping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891900/ https://www.ncbi.nlm.nih.gov/pubmed/35250325 http://dx.doi.org/10.1177/11795549221079185 |
Ejemplares similares
-
Effect of anlotinib combined with ticeorgio for recurrent nasopharyngeal carcinoma: a case report
por: Mao, Jiwei, et al.
Publicado: (2023) -
Combination of Tumor Mutational Burden and DNA Damage Repair Gene Mutations with Stromal/Immune Scores Improved Prognosis Stratification in Patients with Lung Adenocarcinoma
por: Wu, Dongping, et al.
Publicado: (2022) -
Whole brain radiotherapy with radiosensitizer for brain metastases
por: Viani, Gustavo Arruda, et al.
Publicado: (2009) -
Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma
por: Zhuang, Hongqing, et al.
Publicado: (2013) -
Anlotinib combined with whole-brain radiotherapy in non-small cell lung cancer with multiple brain metastases that progressed or developed after at least one lines of prior treatment
por: Kong, Cheng, et al.
Publicado: (2023)